Generate Biomedicines IPO raises $400 million for pivotal test of severe asthma drug

Generate Biomedicines, the flagship company created by Pioneer, aims to inject less frequently than best-selling asthma drugs from partners Amgen and AstraZeneca. Generate's drugs come from “programmable biology” platform technology, which uses artificial intelligence and machine learning to design proteins with desired properties.

The post Generate Biomedicines’ IPO brings $400 million to critical test of severe asthma drug appeared first on MedCity News.